---
layout: default
title: Peginterferon Beta-1A
parent: 僅模型預測 (L5)
nav_order: 256
evidence_level: L5
indication_count: 10
---

# Peginterferon Beta-1A
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Peginterferon beta-1a: From Multiple Sclerosis to Heart Neoplasm

## One-Sentence Summary

Peginterferon beta-1a (internationally marketed as Plegridy) is a pegylated interferon beta-1a normally used for relapsing forms of multiple sclerosis. The TxGNN model predicts a possible signal for **Heart Neoplasm** (score 94.10%), but this is currently a **model-prediction-only** finding — **0 clinical trials** and **0 publications** were found for this drug-disease pair, and the drug itself is **not marketed/authorized** in this jurisdiction (0 licenses on file).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in evidence pack — no licenses/indication text on file. (Externally known use: relapsing forms of multiple sclerosis, marketed as Plegridy) |
| Predicted New Indication | Heart Neoplasm |
| TxGNN Prediction Score | 94.10% |
| Evidence Level | L5 |
| Market Status | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the evidence pack (flagged as data gap DG002, High severity). Based on general pharmacological knowledge, peginterferon beta-1a is a PEGylated form of interferon beta-1a, an immunomodulatory cytokine that reduces immune-mediated inflammation and demyelination in the central nervous system — this is the basis for its approved use in multiple sclerosis. It has no established antineoplastic or cardiac-targeted mechanism.

The link between multiple sclerosis (an autoimmune neurological disease) and heart neoplasm (a rare structural/cardiac tumor) is not mechanistically obvious. The predicted rationale draws an indirect analogy to interferon-alpha, a related but distinct interferon class with documented antiproliferative use in some vascular tumors (e.g., infantile hemangioma). However, no preclinical or clinical data specifically link peginterferon **beta**-1a to cardiac tumor biology — the connection here is a knowledge-graph embedding similarity, not a validated pharmacological hypothesis.

Given the complete absence of supporting clinical trials or literature (confirmed by 0 hits across ClinicalTrials.gov, ICTRP, and PubMed queries), this prediction should be treated as an early-stage hypothesis only, appropriate for the L5 / S0 (model-prediction-only) evidence tier assigned by the scoring system.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Market Information

This drug is **not currently marketed or authorized** in this jurisdiction — there are 0 licenses on file, and no authorization number, product name, dosage form, or approved indication text is available in the evidence pack.

---

## Safety Considerations

Safety data collection is currently **blocked**: label warnings and contraindications could not be retrieved (data gap DG001, **Blocking** severity — no TFDA label/SmPC data parsed yet), and no drug-interaction data was found (query status: not found). This gap prevents the candidate from advancing to the S1 preliminary safety screening stage.

Please refer to the SmPC for safety information once available.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate sits at evidence level L5 (model prediction only) with zero clinical trials or publications across all 10 top-ranked predicted indications, and a Blocking-severity data gap (missing label safety data) prevents even a preliminary safety screen. Several other top-ranked predictions for this drug — notably *heart conduction disease* (rank 3) and *pericardium disease* (rank 10) — are plausibly explained by reversed causality: interferon-beta is a known cause of cardiac conduction abnormalities and pericarditis as adverse drug reactions, not a treatment for them, which raises signal-quality concerns for this entire drug-disease cluster rather than supporting the top prediction.

**To proceed, the following is needed:**
- TFDA/SmPC label data — warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action (DG002)
- Independent preclinical or clinical evidence of interferon beta-1a activity in cardiac neoplasms specifically (not extrapolated from interferon-alpha)
- Causal-direction review of KG-derived predictions that overlap with known adverse drug reactions (heart conduction disease, pericardium disease) before any further evaluation

---

### ⚠️ Note on Other Top-Ranked Candidates

Beyond the primary prediction, ranks 4–9 (borderline ovarian serous tumor, rete ovarii cystadenoma, ovarian mucinous cystadenofibroma, ovarian benign neoplasm, ovarian papillary cystadenoma, malignant ovarian Brenner tumor) form a tight score cluster (88.0–88.9%) of largely benign/rare ovarian entities with no clinical treatment precedent for systemic immunomodulatory therapy — this pattern is more consistent with knowledge-graph node clustering around "ovarian tumor" concepts than with distinct pharmacological signals. None of these carry clinical trial or literature support either. All 10 candidates for this drug are recommended for **Hold** pending the data-gap remediation above.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

